beraprost

Beraprost is a stable, orally active synthetic analogue of prostacyclin (PGI2) classified as a vasodilator and antiplatelet agent. It acts primarily by binding to prostacyclin receptor (IP receptor), leading to inhibition of intracellular calcium release, which causes relaxation of vascular smooth muscle cells and vasodilation. This mechanism also inhibits platelet aggregation. Beraprost is used in the management of conditions associated with poor blood flow such as pulmonary arterial hypertension (PAH), Buerger's disease, peripheral artery disease (PAD), Raynaud’s phenomenon, and arteriosclerosis obliterans. Its oral bioavailability is 50–70%, with a biological half-life of 35–40 minutes. The drug offers an advantage over intravenous prostacyclin therapies due to its oral administration[1][2][3][4][5].

Brand names

Dorner

Other names

beraprost sodiumBeraprostum (Latin)Béraprost (French)